IL300096A - Methods for reducing the concentration of glycosphingolipids in the brain tissue and methods for treating neurodegenerative diseases associated with it - Google Patents

Methods for reducing the concentration of glycosphingolipids in the brain tissue and methods for treating neurodegenerative diseases associated with it

Info

Publication number
IL300096A
IL300096A IL300096A IL30009623A IL300096A IL 300096 A IL300096 A IL 300096A IL 300096 A IL300096 A IL 300096A IL 30009623 A IL30009623 A IL 30009623A IL 300096 A IL300096 A IL 300096A
Authority
IL
Israel
Prior art keywords
methods
treatment
same
neurodegenerative diseases
brain tissue
Prior art date
Application number
IL300096A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL300096A publication Critical patent/IL300096A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL300096A 2020-07-30 2021-07-30 Methods for reducing the concentration of glycosphingolipids in the brain tissue and methods for treating neurodegenerative diseases associated with it IL300096A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063059047P 2020-07-30 2020-07-30
US202063131120P 2020-12-28 2020-12-28
PCT/IB2021/056971 WO2022024062A1 (en) 2020-07-30 2021-07-30 Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same

Publications (1)

Publication Number Publication Date
IL300096A true IL300096A (en) 2023-03-01

Family

ID=77265125

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300096A IL300096A (en) 2020-07-30 2021-07-30 Methods for reducing the concentration of glycosphingolipids in the brain tissue and methods for treating neurodegenerative diseases associated with it

Country Status (11)

Country Link
US (1) US20230372313A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188381A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535483A (cg-RX-API-DMAC7.html)
KR (1) KR20230047146A (cg-RX-API-DMAC7.html)
CN (1) CN116322679A (cg-RX-API-DMAC7.html)
AU (1) AU2021317180A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001362A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187086A1 (cg-RX-API-DMAC7.html)
IL (1) IL300096A (cg-RX-API-DMAC7.html)
MX (1) MX2023001285A (cg-RX-API-DMAC7.html)
WO (1) WO2022024062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
KR20260021150A (ko) 2024-08-05 2026-02-13 충북대학교 산학협력단 Gba1 돌연변이 보인자의 dj-1 발현수준에 따른 파킨슨병의 위험도 예측 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
LT2685986T (lt) * 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
US10617713B2 (en) * 2016-03-08 2020-04-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
EP3452045A1 (en) * 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof

Also Published As

Publication number Publication date
KR20230047146A (ko) 2023-04-06
JP2023535483A (ja) 2023-08-17
WO2022024062A1 (en) 2022-02-03
EP4188381A1 (en) 2023-06-07
CA3187086A1 (en) 2022-02-03
BR112023001362A2 (pt) 2023-02-14
CN116322679A (zh) 2023-06-23
AU2021317180A1 (en) 2023-03-23
US20230372313A1 (en) 2023-11-23
MX2023001285A (es) 2023-02-22

Similar Documents

Publication Publication Date Title
EP4090658A4 (en) THERAPEUTIC AGENTS AND METHODS OF TREATMENT
GB2620511B (en) Device and method for unattended treatment of the patient
PH12022551021A1 (en) Sequential anti-cd19 therapy
IL309317A (en) Treatment of diseases and disorders associated with MTRES1
EP2473037A4 (en) METHOD OF TREATING NEURODEGENERATIVE OR DEGENERATIVE NEUROMUSCULAR DISEASES AND THERAPEUTIC AGENT FOR TREATING THESE DISEASES
IL285171B2 (en) Treatment of skin lesions and itching in patients with PRURIGO NODULARIS
GB202314118D0 (en) Methods of classifying and treating patients
IL302507A (en) Use of human serum albumin to treat diseases
IL313183A (en) Peptides and methods for use in treating pain
EP4486344A4 (en) ORAL PCLX-001 IN THE TREATMENT OF CANCER IN HUMANS
GB202214972D0 (en) Products and methods for use in treating NDP-related diseases
HK40087044A (en) Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same
HUE072558T2 (hu) 1-Metil-1H-pirazol-3-il származékok neovaszkuláris betegségek kezelésében való alkalmazásra
IL315446A (en) Devices and methods for treating stretched skin
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares
IL299749A (en) Device and method for non-invasive personal treatment of skin defects
MX2023001285A (es) Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos.
MX2019015448A (es) Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.
PL4106783T3 (pl) Kompozycja do leczenia chorób skóry i błon śluzowych
CA235144S (en) Apparatus for medical and aesthetic treatment
IL290912A (en) Preparations for the treatment of brain damage and neurodegenerative diseases
HK40082003A (en) Therapeutic agents and methods of treatment
GB202213287D0 (en) Methods of diagnosis and treatment
GB202207570D0 (en) Methods of treatment and diagnosis
HK40111896A (en) Organonitro and sulfoxyalkyl organonitro compounds for use in treating medical disorders